Margaret K Callahan Selected Research

HAD protocol

1/2022

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Margaret K Callahan Research Topics

Disease

50	Neoplasms (Cancer) 05/2024 - 12/2006
39	Melanoma (Melanoma, Malignant) 05/2024 - 03/2012
7	Disease Progression 01/2020 - 07/2015
4	Carcinoma (Carcinomatosis) 11/2023 - 11/2016
3	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2018
3	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2013
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 01/2018
3	Uveal melanoma 01/2016 - 10/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2018
2	Exanthema (Rash) 10/2019 - 11/2016
2	Body Weight (Weight, Body) 10/2017 - 07/2013
2	Inflammation (Inflammations) 02/2016 - 04/2014
2	Leukemia 05/2014 - 12/2012
2	Testicular Neoplasms (Testicular Cancer) 06/2013 - 03/2012
1	Tuberculosis (Tuberculoses) 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Myocarditis (Carditis) 01/2019
1	Hyperglycemia 01/2018
1	Pneumonia (Pneumonitis) 03/2017
1	Pancreatitis 01/2017
1	Fatigue 11/2016
1	Colitis 02/2016
1	Diarrhea 10/2015
1	Prostatic Neoplasms (Prostate Cancer) 04/2014
1	Hypophysitis 04/2014
1	Brain Neoplasms (Brain Tumor) 10/2013

Drug/Important Bio-Agent (IBA)

29	IpilimumabIBA 05/2024 - 03/2012
22	NivolumabIBA 05/2024 - 07/2013
19	Immune Checkpoint InhibitorsIBA 11/2023 - 01/2014
10	Biomarkers (Surrogate Marker)IBA 11/2023 - 03/2013
10	AntibodiesIBA 01/2019 - 09/2011
6	Blocking AntibodiesIBA 01/2021 - 01/2014
5	CTLA-4 AntigenIBA 07/2015 - 07/2013
4	pembrolizumabIBA 01/2021 - 06/2015
4	Programmed Cell Death 1 ReceptorIBA 01/2021 - 07/2013
3	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 05/2014
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2023 - 05/2014
3	B7-H1 AntigenIBA 01/2023 - 03/2017
3	PlatinumIBA 01/2019 - 11/2016
3	Monoclonal AntibodiesIBA 03/2017 - 03/2013
3	AntigensIBA 06/2013 - 02/2008
2	Amylases FDA Link 01/2017 - 11/2016
2	Lipase (Acid Lipase)FDA Link 01/2017 - 11/2016
2	LigandsIBA 07/2015 - 11/2012
2	VemurafenibIBA 05/2014 - 12/2012
2	EpitopesIBA 02/2009 - 12/2006
1	CytokinesIBA 05/2024
1	Phenformin (Fenformin)IBA 12/2023
1	trametinibIBA 12/2023
1	dabrafenibIBA 12/2023
1	Adenylate KinaseIBA 12/2023
1	relatlimabIBA 01/2023
1	Inducible T-Cell Co-Stimulator ProteinIBA 01/2022
1	Interleukin-2 (IL2)IBA 01/2022
1	varlilumabIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2020
1	atezolizumabIBA 10/2018
1	EnzymesIBA 01/2017
1	PolyaminesIBA 02/2016
1	Vitamin B Complex (B Vitamins)IBA 02/2016
1	pasireotideIBA 01/2016
1	Insulin (Novolin)FDA Link 01/2016
1	TOR Serine-Threonine KinasesIBA 01/2016
1	Everolimus FDA Link 01/2016
1	cobimetinibIBA 05/2014
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 05/2014
1	Follicle Stimulating Hormone (Follitropin)FDA Link 04/2014
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 04/2014
1	Adrenocorticotropic Hormone (ACTH)FDA Link 04/2014
1	Proteins (Proteins, Gene)FDA Link 10/2013
1	Integrin alpha4beta1 (VLA-4)IBA 06/2012
1	Oncogene Proteins (Oncogene Protein)IBA 06/2012
1	Protein Isoforms (Isoforms)IBA 06/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 06/2012
1	Cancer VaccinesIBA 09/2011
1	Peptides (Polypeptides)IBA 02/2009
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 02/2009
1	Histocompatibility Antigens Class IIBA 02/2008
1	Peptide FragmentsIBA 02/2008

Therapy/Procedure

29	Therapeutics 01/2023 - 03/2013
21	Immunotherapy 04/2023 - 02/2009
3	Time-to-Treatment 01/2020 - 10/2015
3	Radiotherapy 01/2020 - 03/2012
2	Drug Therapy (Chemotherapy) 01/2020 - 11/2016
2	Aftercare (After-Treatment) 01/2020 - 01/2020
1	HAD protocol 01/2022
1	Metastasectomy 04/2020
1	Retreatment 01/2020
1	Secondary Prevention 01/2018
1	Injections 04/2014
1	Immunomodulation 03/2013